Skip to content

US · VYGR · BIOTECHNOLOGY

Voyager Therapeutics, Inc. (VYGR) intrinsic value and stock valuation

$1.53as of 2026-11-21 · Mkt cap 187.31M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Voyager Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values VYGR with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from VYGR’s statements →

Voyager Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Lexington, MA 02421 voyagertherapeutics.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$40.4M-25.1% 5y CAGRd
20132025
Net income
-$-119.72M
20132025
Free cash flow
-$-135.06M
20132025
Total equity
$196.1M+4.9% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$40.4M$80M$250M$40.9M$37.4M
Operating income-$-131.84M-$-83.29M$122M-$-50.84M-$-73.62M
Net income-$-119.72M-$-65M$132.3M-$-46.41M-$-71.2M
EPSd-$-2.04M-$-1.13M$2.97M-$-1.21M-$-1.89M
Operating cash flow-$-132.47M-$-15.31M$77.9M-$-12.51M-$-53.52M
Capital expenditure-$-2.6M-$-3.52M-$-3.26M-$-2.49M-$-1.61M
Free cash flow-$-135.06M-$-18.83M$74.7M-$-15M-$-55.13M
Total assets$252.3M$393.1M$351.3M$159.4M$193.9M
Total debt$36.5M$43.7M$20.3M$23.1M$44.2M
Net debt-$-28.8M-$-27.64M-$-48.51M-$-75.83M-$-73.25M
Total equity$196.1M$299.8M$236.3M$59M$95.1M
Cash and short-term investments$196.5M$266.7M$230.9M$118.9M$132.5M
Income statement
20252024202320222021
Revenue$40.4M$80M$250M$40.9M$37.4M
Cost of revenue$132.3M$0.00$92.2M$55.8M$73.8M
Gross profit-$-91.9M$80M$157.8M-$-14.86M-$-36.37M
Research and development expenses$134.7M$127.4M$92.2M$60.8M$73.8M
Selling, general and administrative expenses$36.4M$35.9M$35.8M$31M$37.3M
Other expenses-$-131.17M$0.00-$-92.17M-$-55.76M-$-73.79M
Operating expenses$39.9M$163.3M$35.8M$36M$37.3M
Cost and expenses$172.2M$163.3M$128M$91.7M$111M
Interest income$10.6M$18.3M$11.7M$1.79M$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$4.06M$4.73M$4.44M$6.19M$5.17M
Ebitda-$-115.52M-$-59.61M$138.2M-$-39.65M-$-66.03M
Operating income-$-131.84M-$-83.29M$122M-$-50.84M-$-73.62M
Total other income/expenses, net$12.3M$19M$11.7M$4.45M$2.42M
Income before tax-$-119.58M-$-64.34M$133.7M-$-46.39M-$-71.2M
Income tax expense$140K$670K$1.41M$20K$0.00
Net income-$-119.72M-$-65M$132.3M-$-46.41M-$-71.2M
Weighted average shares outstanding$58.7M$57.7M$43M$38.4M$37.7M
Weighted average diluted shares outstanding$58.7M$57.7M$44.6M$38.4M$37.7M
Balance sheet
20252024202320222021
Cash and short-term investments$196.5M$266.7M$230.9M$118.9M$132.5M
Net receivables$1.76M$4.49M$84.5M$640K$750K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$202.7M$276.8M$319.7M$124.5M$136.7M
Property, plant and equipment, net$41.6M$47.7M$30M$33.3M$55.4M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$65.7M$0.00$0.00$0.00
Total non-current assets$49.6M$116.2M$31.6M$34.9M$57.2M
Total assets$252.3M$393.1M$351.3M$159.4M$193.9M
Accounts payable$5.01M$4M$1.6M$2.57M$570K
Short-term debt$7.84M$7.23M$3.2M$2.83M$5.57M
Deferred revenue$1.59M$24.4M$42.9M$59.4M$33.9M
Total current liabilities$26.5M$49.8M$64.5M$72.6M$51M
Long-term debt$28.7M$36.5M$17.1M$20.3M$38.6M
Deferred revenue, non-current$0.00$6M$32.4M$6.45M$8.21M
Total non-current liabilities$29.7M$43.5M$50.5M$27.8M$47.8M
Capital lease obligations$36.5M$43.7M$20.3M$23.1M$44.2M
Total liabilities$56.2M$93.3M$115M$100.3M$98.8M
Common stock$60K$60K$40K$40K$40K
Retained earnings-$-445.9M-$-326.18M-$-261.18M-$-393.51M-$-347.1M
Accumulated other comprehensive income (loss)$30K-$-410K-$-50K-$-220K-$-140K
Total equity$196.1M$299.8M$236.3M$59M$95.1M
Total investments$131.2M$261M$162.1M$19.9M$15.1M
Total debt$36.5M$43.7M$20.3M$23.1M$44.2M
Net debt-$-28.8M-$-27.64M-$-48.51M-$-75.83M-$-73.25M
Cash flow statement
20252024202320222021
Net income-$-119.72M-$-65M$132.3M-$-46.41M-$-71.2M
Depreciation and amortization$4.06M$4.73M$4.44M$6.19M$5.17M
Stock-based compensation$14.8M$14.8M$11.2M$9.34M$11.3M
Change in working capital-$-28.76M$34.9M-$-66.56M$20.5M$3.29M
Accounts receivable$270K$81.3M-$-83.23M$470K$7.28M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.02M$2.39M-$-960K$1.99M-$-60K
Net cash provided by operating activities-$-132.47M-$-15.31M$77.9M-$-12.51M-$-53.52M
Investments in property, plant and equipment-$-2.6M-$-3.52M-$-3.26M-$-2.49M-$-1.61M
Acquisitions, net$0.00$0.00$138.4M$0.00$0.00
Net cash used for investing activities$125.5M-$-94.86M-$-141.64M-$-7.34M$65.9M
Common stock issued$820K$114M$33.7M$1.11M$610K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$820K$114M$33.7M$1.11M$610K
Net change in cash-$-6.21M$3.85M-$-30.08M-$-18.47M$13M
Cash at end of period$68M$74.2M$70.4M$99M$117.4M
Operating cash flow-$-132.47M-$-15.31M$77.9M-$-12.51M-$-53.52M
Capital expenditure-$-2.6M-$-3.52M-$-3.26M-$-2.49M-$-1.61M
Free cash flow-$-135.06M-$-18.83M$74.7M-$-15M-$-55.13M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Voyager Therapeutics, Inc.

        Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.

        CEO
        Alfred W. Sandrock Jr.
        Employees
        141
        Beta
        1.27

        Explore

        Frequently asked questions

        What is the intrinsic value of Voyager Therapeutics, Inc. (VYGR)?

        Voyager Therapeutics, Inc. (VYGR) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is VYGR undervalued?

        VYGR trades at a price of $1.53 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.